Chronic Myeloid Leukemia
Discovery pinpoints cause of two types of leukemia, providing insights into new treatment approach
(Medical Xpress)—Patients with two forms of leukemia, who currently have no viable treatment options, may benefit from existing drugs developed for different types of cancer, according to a study conducted by researchers ...
Cancer
May 10, 2013 |
5 / 5 (1) |
0
|
Mutations in CSF3R common in CNL, atypical CML
(HealthDay)—In the war against cancer, it looks like matchmaking—between genes and drugs—could be an important tool, according to new research into the genetic underpinnings of two rare forms of leukemia.
Cancer
May 09, 2013 |
not rated yet |
0
Doctors say cancer drug costs are too high
More than 100 doctors from around the world have signed a letter decrying the high cost of cancer drugs which reach $100,000 per year or more, and calling for pharmaceutical companies to ease prices.
Medications
Apr 26, 2013 |
5 / 5 (4) |
2
Leading leukemia experts: High leukemia treatment costs may be harming patients
The increasing cost of treatments for chronic myeloid leukemia (CML) in the United States has reached unsustainably high levels and may be leaving many patients under- or untreated because they cannot afford care, according ...
Cancer
Apr 25, 2013 |
not rated yet |
0
Three cancer scientists awarded $500K Nmedical prize
Three scientists at universities in Pennsylvania, Illinois and Oregon whose research has helped transform cancer treatment will share one of the richest prizes in medicine and biomedical research.
Cancer
Apr 16, 2013 |
5 / 5 (2) |
0
Drug maker Novartis loses India patent battle (Update)
India's Supreme Court on Monday rejected drug maker Novartis AG's attempt to patent an updated version of a cancer drug in a landmark decision that health activists say ensures poor patients around the world ...
Medications
Apr 01, 2013 |
5 / 5 (3) |
0
India's top court to deliver Novartis judgment
India's Supreme Court is to rule Monday on a landmark patent case involving Swiss drugmaker Novartis AG that focuses on demands by major companies that their investments be protected, against Indian companies ...
Medications
Mar 31, 2013 |
not rated yet |
0
Gleevec's latest approval is for pediatric cancer
(HealthDay)—The anti-cancer drug Gleevec (imatinib) has received new U.S. Food and Drug Administration approval to treat the most common type of pediatric cancer, affecting some 2,900 children each year, the agency said ...
Cancer
Jan 25, 2013 |
not rated yet |
0
Study of cancer cell metabolism yields new insights on leukemia
University of Rochester Medical Center scientists have proposed a new reason why acute myeloid leukemia, one of the most aggressive cancers, is so difficult to cure: a subset of cells that drive the disease appear to have ...
Cancer
Jan 17, 2013 |
not rated yet |
0
Drug targets hard-to-reach leukemia stem cells responsible for relapses
Researchers at the University of California, San Diego School of Medicine have discovered that hard-to-reach, drug-resistant leukemia stem cells (LSCs) that overexpress multiple pro-survival protein forms ...
Cancer
Jan 17, 2013 |
3.7 / 5 (3) |
0
|
Enzyme accelerates malignant stem cell cloning in chronic myeloid leukemia
An international team, headed by researchers at the University of California, San Diego School of Medicine, has identified a key enzyme in the reprogramming process that promotes malignant stem cell cloning ...
Cancer
Dec 24, 2012 |
5 / 5 (1) |
0
|
Options increase for CML patients failed by existing drugs
The U.S. Food and Drug Administration (FDA) this month expanded the options for patients with chronic myeloid leukemia and one form of acute lymphoblastic leukemia that carries the Philadelphia chromosome (Ph+ALL). It approved ...
Cancer
Dec 21, 2012 |
not rated yet |
0
Iclusig approved for rare leukemias
(HealthDay)—Iclusig (ponatinib) has been approved by the U.S. Food and Drug Administration to treat two rare forms of leukemia..
Cancer
Dec 16, 2012 |
not rated yet |
0
Temple scientists target DNA repair to eradicate leukemia stem cells
Despite treatment with imatinib, a successful drug that targets chronic myeloid leukemia (CML), a deadly type of cancer, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant ...
Cancer
Dec 09, 2012 |
5 / 5 (3) |
0
|
ATRA and arsenic trioxide versus ATRA and idarubicin for newly diagnosed, non high-risk acute promyelocytic
New research demonstrates the efficacy of the first curative treatment for acute promyelocytic leukemia (APL) that does not include chemotherapy, marking an important step toward front-line use of targeted therapies for acute ...
Cancer
Dec 09, 2012 |
not rated yet |
0
Chronic myelogenous (or myeloid) leukemia (CML), also known as chronic granulocytic leukemia (CGL), is a cancer of the white blood cells. It is a form of leukemia characterized by the increased and unregulated growth of predominantly myeloid cells in the bone marrow and the accumulation of these cells in the blood. CML is a clonal bone marrow stem cell disorder in which proliferation of mature granulocytes (neutrophils, eosinophils, and basophils) and their precursors is the main finding. It is a type of myeloproliferative disease associated with a characteristic chromosomal translocation called the Philadelphia chromosome. CML is now largely treated with tyrosine kinase inhibitors (TKIs), such as imatinib, dasatinib, or nilotinib, which have led to dramatically improved survival rates since their introduction in the last decade.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
Latest Spotlight News
Researchers find common childhood asthma unconnected to allergens or inflammation
Little is known about why asthma develops, how it constricts the airway or why response to treatments varies between patients. Now, a team of researchers at Weill Cornell Medical College, Columbia University Medical Center ...
Scientists discover molecule triggers sensation of itch
Scientists at the National Institutes of Health report they have discovered in mouse studies that a small molecule released in the spinal cord triggers a process that is later experienced in the brain as the sensation of ...
Multiple research teams unable to confirm high-profile Alzheimer's study
Teams of highly respected Alzheimer's researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.
Brain uses internal 'average voice' prototype to identify who is talking
(Medical Xpress)—The human brain is able to identify individuals' voices by comparing them against an internal 'average voice' prototype, according to neuroscientists.
Drug reverses Alzheimer's disease deficits in mice, research confirms
An anti-cancer drug reverses memory deficits in an Alzheimer's disease mouse model, University of Pittsburgh Graduate School of Public Health researchers confirm in the journal Science.
Antibiotics: A new understanding of sulfonamide nervous system side effects
Since the discovery of Prontosil in 1932, sulfonamide antibiotics have been used to combat a wide spectrum of bacterial infections, from acne to chlamydia and pneumonia. However, their side effects can include serious neurological ...
Economic incentives increase blood donation without negative consequences
Can economic incentives such as gift cards, T-shirts, and time off from work motivate members of the public to increase their donations of blood?
Motion quotient: IQ predicted by ability to filter motion (w/ video)
A brief visual task can predict IQ, according to a new study. This surprisingly simple exercise measures the brain's unconscious ability to filter out visual movement. The study shows that individuals whose ...
The secret lives, and deaths, of neurons
As the human body fine-tunes its neurological wiring, nerve cells often must fix a faulty connection by amputating an axon—the "business end" of the neuron that sends electrical impulses to tissues or other ...
Protein preps cells to survive stress of cancer growth and chemotherapy
Scientists have uncovered a survival mechanism that occurs in breast cells that have just turned premalignant-cells on the cusp between normalcy and cancers-which may lead to new methods of stopping tumors.
